Investors / United Kingdom / 4BIO Capital
4BIO Capital
Venture capital · London, United Kingdom · Europe
4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector. It invests in, supports and grows early stage companies developing treatments in areas of high unmet medical need.
Invests inHealthcare & Biotech
In its own wordsadvanced therapiescell therapygene therapyrna therapeuticsmicrobiomelife sciences
Your fit with 4BIO Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fits4BIO Capital lists 7 checked portfolio companies on its own site and is named in 8 funding rounds, 5 of them as lead. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 43% of its companies are based in United Kingdom. It invests most often alongside IQ Capital, Kerna Ventures and Mission BioCapital.
Counts come from funding rounds that name 4BIO Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 38% |
| Series A | 50% |
| Series B | 13% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 7 | 5 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 12th | 7 companies |
| Recent activity | 91th | 7 rounds in 12 months |
| Early stage | 65th | 38% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| IQ Capital | 2 |
| Kerna Ventures | 2 |
| Mission BioCapital | 2 |
| AIN Ventures | 1 |
| Abingworth | 1 |
| Angelini Ventures | 1 |
| BrightEdge | 1 |
| British Business Bank | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare 4BIO Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with 4BIO Capital| Date | Company | Stage |
|---|---|---|
| 10 Nov 2026 | Series A Led | |
| 16 Oct 2026 | Series A | |
| 13 Oct 2026 | Seed Led | |
| 29 Sept 2026 | Seed Led | |
| 8 Sept 2026 | Seed Led | |
| 5 May 2026 | Series A Led | |
| 6 Oct 2025 | Series A |
Round details for 4BIO Capital
Amounts, full round histories and every co-investor in 4BIO Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
7 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AptaDir develops RNA-based therapeutics to reprogram DNA methylation in disease conditions | Healthcare & Biotech | Sept 2026Seed | Funding round | |
| The company is developing a new class of RNA therapeutics to revolutionize cancer therapy. | Healthcare & Biotech | Sept 2026Seed | Funding round | |
| Cytospire Therapeutics develops next generation immune cell engagers, including multispecific antibodies and gamma delta T cell engagers, for cancer therapies. | Healthcare & Biotech | May 2026Series A | Funding round | |
| Estuary Bio is developing gene therapies to treat autosomal dominant polycystic kidney disease (ADPKD) | Healthcare & Biotech | Oct 2026Series A | Funding round | |
| Oyster Therapeutics develops smaller protein degrader therapeutics to reach new biological targets and bigger populations, starting with neurodegenerative disease. | Healthcare & Biotech | Nov 2026Series A | Funding round | |
| Trogenix develops precision cancer treatments using gene therapy | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| UndecimalBio pairs massive scale combinatorial chemistry with transformer-based AI to guide siRNA therapeutics into the tissues that need them. | Healthcare & Biotech | Oct 2026Seed | Funding round |
About this data
site last read 5 Nov 2026- Site
- 4biocapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 6 Oct 2025
- Companies checked
- 7
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get 4BIO Capital's profile as data
Pull 4BIO Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/4biocapital.com
# also
GET /v1/firms/4biocapital.com/portfolio
GET /v1/firms/4biocapital.com/coinvestors
GET /v1/firms/4biocapital.com/news